QURE insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 90% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 12 officers and directors who sold. 12 are left out

Left out: Matthew Kapusta, Christian Klemt, Walid Abi-Saab, Jeannette Potts, Robert Gut, Madhavan Balachandran, Jeremy Springhorn, David Meek, Leonard Post, Rachelle Jacques, Jack Kaye and Kylie O'Keefe (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Matthew Kapusta

CEO, Managing Director, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$12.9M94% planned, 6% to cover taxes

Jack Kaye

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.7M98% planned, 2% to cover taxes

Walid Abi-Saab

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.6M97% planned, 3% to cover taxes

Robert Gut

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.8MDisclosed plan

Madhavan Balachandran

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$859K94% planned, 6% to cover taxes

All 12 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Jul 2, 2026Matthew Kapusta sold 21K shares ($952K) under a disclosed trading plan. 21K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Matthew Kapusta CEO, Managing Director, Director	21,082	$45.16	n/a	n/a	Jul 2, 2026	Jul 7, 2026

Common questions

Is the uniQure N.V. CEO selling stock?

Yes. Matthew Kapusta sold 324K shares ($12.9M) in the past 12 months, 94% of it under a trading plan disclosed in the filings.

Why are uniQure N.V. insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 90% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 10% were to cover taxes. A trading plan schedules sales in advance.

Are any uniQure N.V. insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold12 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Matthew Kapusta CEO, Managing Director, Director	$12.9M 324K shares	Not confirmed share of stake is being verified. Why	94% under a disclosed plan, 6% to cover taxes
Jack Kaye Director	$2.7M 76K shares	Not confirmed share of stake is being verified. Why	98% under a disclosed plan, 2% to cover taxes
Walid Abi-Saab Chief Medical Officer	$2.6M 79K shares	Not confirmed share of stake is being verified. Why	97% under a disclosed plan, 3% to cover taxes
Robert Gut Director	$1.8M 67K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Madhavan Balachandran Director	$859K 24K shares	Not confirmed share of stake is being verified. Why	94% under a disclosed plan, 6% to cover taxes
Kylie O'Keefe Chief Customer & Strat Officer	$431K 16K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Christian Klemt Chief Financial Officer	$382K 31K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Jeannette Potts Chief Legal Officer	$261K 17K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Jeremy Springhorn Director	$54K 2K shares	Not confirmed share of stake is being verified. Why	To cover taxes
David Meek Director	$54K 2K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Leonard Post Director	$54K 2K shares	Not confirmed share of stake is being verified. Why	To cover taxes
Rachelle Jacques Director	$54K 2K shares	Not confirmed share of stake is being verified. Why	To cover taxes

The full ownership picture0 of 12 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Matthew Kapusta

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Matthew Kapusta are complete.

CEO, Managing Director, Director

n/a

−324K

n/a

Vesting, gifts, unvested awards and holding lines for Matthew Kapusta

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Matthew Kapusta are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
45,862	$31.71	Jan 25, 2029	$650K
259,500	$5.59	Mar 1, 2034	$10.5M
171,000	$10.90	Mar 3, 2025	$6.0M
113,800	$9.04	Mar 4, 2036	$4.2M

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Christian Klemt

Chief Financial Officer

n/a

−31K

n/a

Vesting, gifts, unvested awards and holding lines for Christian Klemt

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christian Klemt are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
85,500	$5.59	Mar 1, 2034	$3.4M
126,000	$10.90	Mar 3, 2035	$4.4M
63,900	$9.04	Mar 4, 2036	$2.4M

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Walid Abi-Saab

Chief Medical Officer

n/a

−79K

n/a

Vesting, gifts, unvested awards and holding lines for Walid Abi-Saab

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Walid Abi-Saab are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,500	$5.59	Mar 1, 2034	$2.0M
66,000	$10.90	Mar 3, 2035	$2.3M
67,200	$9.04	Mar 4, 2036	$2.5M

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Jeannette Potts

Chief Legal Officer

n/a

−17K

n/a

Vesting, gifts, unvested awards and holding lines for Jeannette Potts

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeannette Potts are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
85,500	$5.59	Mar 1, 2034	$3.4M
60,000	$10.90	Mar 3, 2035	$2.1M
57,200	$9.04	Mar 4, 2036	$2.1M

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Robert Gut

Director

n/a

−67K

n/a

Vesting, gifts, unvested awards and holding lines for Robert Gut

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Robert Gut are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,630	$16.22	Jun 11, 2035	$464K
13,980	$26.82	Jun 10, 2036	$267K

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Madhavan Balachandran

Director

n/a

−24K

n/a

Vesting, gifts, unvested awards and holding lines for Madhavan Balachandran

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Madhavan Balachandran are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,840	$4.57	Jun 19, 2034	$655K
15,630	$16.22	Jun 11, 2035	$464K
13,980	$26.82	Jun 10, 2036	$267K

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Jeremy Springhorn

Director

n/a

−2K

n/a

Vesting, gifts, unvested awards and holding lines for Jeremy Springhorn

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jeremy Springhorn are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,840	$4.57	Jun 19, 2034	$655K
15,630	$16.22	Jun 11, 2035	$464K
13,980	$26.82	Jun 10, 2036	$267K

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

David Meek

Director

n/a

−2K

n/a

Vesting, gifts, unvested awards and holding lines for David Meek

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Meek are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,840	$4.57	Jun 19, 2034	$655K
15,630	$16.22	Jun 11, 2035	$464K
13,980	$26.82	Jun 10, 2036	$267K

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Leonard Post

Director

n/a

−2K

n/a

Vesting, gifts, unvested awards and holding lines for Leonard Post

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Leonard Post are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,840	$4.57	Jun 19, 2034	$655K
15,630	$16.22	Jun 11, 2035	$464K
13,980	$26.82	Jun 10, 2036	$267K

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Rachelle Jacques

Director

n/a

−2K

n/a

Vesting, gifts, unvested awards and holding lines for Rachelle Jacques

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rachelle Jacques are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,840	$4.57	Jun 19, 2034	$655K
15,630	$16.22	Jun 11, 2035	$464K
13,980	$26.82	Jun 10, 2036	$267K

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Jack Kaye

Director

n/a

−76K

n/a

Vesting, gifts, unvested awards and holding lines for Jack Kaye

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jack Kaye are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
15,840	$4.57	Jun 19, 2034	$655K
15,630	$16.22	Jun 11, 2035	$464K
13,980	$26.82	Jun 10, 2036	$267K

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Kylie O'Keefe

Chief Customer & Strat Officer

n/a

−16K

n/a

Vesting, gifts, unvested awards and holding lines for Kylie O'Keefe

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kylie O'Keefe are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
180,000	$16.22	Jun 11, 2035	$5.3M
31,900	$9.04	Mar 4, 2036	$1.2M

Estimate: options held × ($45.89 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Holdings and share of stake for uniQure N.V. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$22.1M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $22.1M across 642,079 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $19.8M · 90%

10%

The lighter segment is sales with no plan disclosed in the filing ($2.3M), including tax-related sales outside a plan.

Taxes

$2.3M of sales (10.6%) cite tax obligations in their footnotes, $74K of them also under a plan. Example: Walid Abi-Saab, Jun 26, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Matthew Kapusta CEO, Managing Director, Director	324K	$12.9M	94%	58%	Feb 25, 2026 to Jul 2, 2026
Jack Kaye Director	76K	$2.7M	98%	12%	Nov 4, 2025 to Jun 30, 2026
Walid Abi-Saab Chief Medical Officer	79K	$2.6M	97%	12%	Mar 2, 2026 to Jun 30, 2026
Robert Gut Director	67K	$1.8M	100%	8%	Nov 6, 2025 to Jun 11, 2026
Madhavan Balachandran Director	24K	$859K	94%	4%	Jun 11, 2026 to Jun 17, 2026
Kylie O'Keefe Chief Customer & Strat Officer	16K	$431K	0%	2%	Jun 11, 2026 to Jun 11, 2026
Christian Klemt Chief Financial Officer	31K	$382K	0%	2%	Feb 25, 2026 to Mar 4, 2026
Jeannette Potts Chief Legal Officer	17K	$261K	0%	1%	Mar 2, 2026 to Jun 15, 2026
Jeremy Springhorn Director	2K	$54K	0%	0.2%	Jun 11, 2026 to Jun 11, 2026
David Meek Director	2K	$54K	0%	0.2%	Jun 11, 2026 to Jun 11, 2026
Leonard Post Director	2K	$54K	0%	0.2%	Jun 11, 2026 to Jun 11, 2026
Rachelle Jacques Director	2K	$54K	0%	0.2%	Jun 11, 2026 to Jun 11, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$2.0M	$2.0M	$0	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$805K	$805K	$0	$0
Feb 2026	$444K	$0	$444K	$0
Mar 2026	$848K	$0	$848K	$0
Apr 2026	$0	$0	$0	$0
May 2026	$1.1M	$1.1M	$0	$0
Jun 2026	$15.9M	$14.9M	$967K	$0
Jul 2026	$952K	$952K	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$0	$0	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 3x the 5-year average. 12 insiders sold; the average is 12 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	642K	12	$22.1M
Oct 16, 2025 1 year earlier	470K	11	$13.2M
Oct 16, 2024 2 years earlier	83K	13	$490K
Oct 17, 2023 3 years earlier	145K	13	$2.8M
Oct 17, 2022 4 years earlier	112K	12	$2.4M
Oct 17, 2021 5 years earlier	211K	11	$7.8M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty12 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for uniQure N.V. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology431 filings on record, 36 filed in the 12-month period, and how we read them

All 431 Forms 3, 4 and 5 on record for uniQure N.V. (SEC CIK 1590560), filed from Jan 3, 2017 to Jul 7, 2026; 36 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (17)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Pierre Caloz	Jun 20, 2024	115,707 shares, last reported balance as of Jun 17, 2024
Paula Soteropoulos	Jun 17, 2024	20,203 shares, last reported balance as of Jun 13, 2024
Ricardo Dolmetsch	Sep 20, 2023	163,404 shares, last reported balance as of Sep 18, 2023
Alexander Kuta III	Mar 9, 2023	116,959 shares, last reported balance as of Mar 7, 2023
Philip Astley-Sparke	Mar 4, 2021	9,946 shares, last reported balance as of Mar 2, 2021
Sander van Deventer	Mar 2, 2020	113,029 shares, last reported balance as of Feb 27, 2020
David Schaffer	Mar 2, 2020	179,038 shares, last reported balance as of Feb 27, 2020
Scott McMillan	Jan 30, 2019	20,432 shares, last reported balance as of Jan 28, 2019
Steven Zelenkofske	Jun 8, 2018	159,458 shares, last reported balance as of Jun 6, 2018
B.V ForUniqure	May 16, 2018	4,376,883 shares, last reported balance as of Apr 23, 2018
Maria Cantor	Jan 30, 2018	92,439 shares, last reported balance as of Jan 26, 2018
Jonathan Garen	Jan 30, 2018	93,638 shares, last reported balance as of Jan 26, 2018
Paul Firuta	Jan 30, 2018	93,817 shares, last reported balance as of Jan 26, 2018
Harald Petry	Jun 29, 2017	No balance on record
Maiken Keson-Brookes	Feb 21, 2017	No balance on record
Christian Meyer	Feb 21, 2017	No balance on record
William Lewis	Jan 31, 2017	No balance on record

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

uniQure N.V. insiders sold $22.1M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the uniQure N.V. CEO selling stock?

Why are uniQure N.V. insiders selling?

Are any uniQure N.V. insiders buying?

The evidence

Taxes

Sales by month